Covaxin Has No Serious Side-Effects: AIIMS

Covaxin may provide immunity against Covid-19 for about 9 to 12 months and there has been no death reported so far due to Covaxin, nor has there been any case of major side-effects.

Covaxin was found to be effective against Covid-19 for 9 to 12 months, and there may be a booster shot after this period elapses, said Y.K. Gupta, the President of AIIMS Bhopal and Jammu.

Stressing on the safety and effectiveness of //Covaxin, Gupta, former Dean (Academics), and ex-Head, Department of Pharmacology, AIIMS, New Delhi, said that no death has been reported so far due to Covaxin, nor has there been any case of major side-effects, adding that more clarity will emerge by March end when data from Phase 3 trials will be available to establish the efficacy of Covaxin.

Bharat Biotech Covaxin Not Approved: Experts
The data provided by Bharat Biotech for its coronavirus vaccine 'Covaxin' is not sufficient for emergency use and hence, has not been approved by the experts.

‘Covaxin may provide immunity against Covid-19 for about 9 to 12 months and there has been no death reported so far due to Covaxin, nor has there been any case of major side-effects.’

The approval for Covaxin, the homegrown vaccine developed by Bharat Biotech, had faced unrelenting criticism, especially when it was administered to scores of healthcare workers during Phase 1 of the vaccination drive. The critics have badgered Covaxin's approval in the absence of Phase 3 trial data.

Speaking to IANS, Gupta said, "These are not scientifically correct claims. Covaxin was approved for emergency use and the data from Phase 1 and Phase 2 trials, and the ongoing Phase 3 trials, suggest that it is safe and effective, and by March-end tentatively, the data from Phase 3 trials will be available to establish its efficacy."

When queried on the safety of Covaxin and people developing side-effects after its administration, Gupta said: "The vaccine is being given to lakhs of people, and there are hardly any serious side-effects. Rather there are only minor side-effects, whuihg indicate the effectiveness of the vaccine. No death has been caused by Covaxin so far."

No Need To Hesitate To take Covaxin: AIIMS
After the Lancet study, the raging controversy over the efficacy of Covaxin, India's first indigenous COVID-19 vaccine, should not exist.

Commenting on India's vaccine technology in the backdrop the new mutant coronavirus strain reported in a few countries, Gupta said: "The Indian vaccine technology with minor tweaking has the potential to address these new strains."

Addressing the attack on the efficacy of Covaxin by many scientists globally, Yadav said they have made irresponsible comments.

COVID-19 Vaccine COVAXIN's Animal Trial Gets Robust Immune Responses
In animal studies, the COVID-19 vaccine candidate, COVAXIN has shown positive efficacy and generated robust immune responses, said Bharat Biotech International Limited.

"It is better to take Covaxin than having irreversible damage to lungs due to Covid-19. By March end, we will have more real-life evidence and there will be more clarity. If Phase 3 trials give good results, it will be a matter of pride... No adverse event has been reported so far," said Gupta.

He added that the regulator approves a drug if its efficacy is found to be over 50 per cent, which has been the case for Covaxin, and emphasised that different hypothesis and extrapolation suggest that it will be effective.

Bharat Biotech Claims Covaxin Generated Excellent Safety Data
Bharat Biotech claims that COVID-19 vaccine generated excellent safety data with robust immune responses to multiple viral proteins that persist.

"There should not be any vaccine hesitancy," Gupta said.

Source-IANS